Skip to main content Back to Top
Advertisement

8/10/2020

Carisoprodol Tablets

Products Affected - Description

    • Carisoprodol tablet, Teva, 350 mg, bottle, 100 count, NDC 00591-5513-01
    • Carisoprodol tablet, Teva, 350 mg, bottle, 500 count, NDC 00591-5513-05

Reason for the Shortage

    • Cadista discontinued carisoprodol tablets.
    • Endo Pharmaceuticals discontinued carisoprodol tablets.
    • Mylan has Soma tablets available.
    • Rising discontinued carisoprodol tablets.
    • Sciegen has carisoprodol tablets available.
    • Teva has carisoprodol on shortage due to manufacturing delay.

Available Products

    • Soma tablet, Mylan, 250 mg, bottle, 30 count, NDC 00037-2250-30
    • Soma tablet, Mylan, 250 mg, bottle, 100 count, NDC 00037-2250-10
    • Soma tablet, Mylan, 350 mg, bottle, 100 count, NDC 00037-2001-01
    • Carisoprodol tablet, Carlsbad Tech, 350 mg, bottle, 100 count, NDC 61442-0451-01
    • Carisoprodol tablet, Carlsbad Tech, 350 mg, bottle, 500 count, NDC 61442-0451-05
    • Carisoprodol tablet, Carlsbad Tech, 350 mg, bottle, 1000 count, NDC 61442-0451-10
    • Carisoprodol tablet, Sciegen Pharmaceuticals, Inc., 350 mg, bottle, 100 count, NDC 50228-0109-01
    • Carisoprodol tablet, Sciegen Pharmaceuticals, Inc., 350 mg, bottle, 500 count, NDC 50228-0109-05
    • Carisoprodol tablet, Sciegen Pharmaceuticals, Inc., 350 mg, bottle, 1000 count, NDC 50228-0109-10
    • Carisoprodol tablet, Teva, 350 mg, bottle, 1000 count, NDC 00591-5513-10

Estimated Resupply Dates

    • Teva has carisoprodol 350 mg tablets in 100 count and 500 count bottles on back order and the company estimates a release date in early-September 2020.

Updated

Updated August 10, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created April 25, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.